Reading ALZN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALZN free→Reading ALZN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALZN free→QuarterlyIQ Insights · ALZN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 20, 2026, Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”) received a letter (the “ Letter ”) from the Listing Qualifications staff (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 (the “ Form 10-Q ”), did not satisf…
Entry into a Material Definitive Agreement. On March 6, 2026, Alzamend Neuro, Inc. (the “ Company ”) entered into an At-the-Market Issuance Sales Agreement (the “ Sales Agreement ”) with Ascendiant Capital Markets, LLC, as sales agent (the “ Agent ”) to sell shares of its common stock, par value $0.0001 (the “ Common Stock ”), having an aggregate offering price of up to $3.0 million (the “ Shares ”) from time to time, through an “at the market offering” (the “ ATM Offering ”) as defined in Ru…
Unregistered Sales of Equity Securities. Between October 1, 2025 and October 8, 2025, Alzamend Neuro, Inc. (the “ Company ”) issued an aggregate of 361,743 shares of common stock, par value $0.0001 per share (“ Common Stock ”) upon conversion of an aggregate of approximately 839.2 shares of Series B Convertible Preferred Stock. The shares of Common Stock were issued in reliance upon exemption from the registration requirements under Section 4(a)(2) under the Securities Act. As of October 8, 2…
Unregistered Sales of Equity Securities. Between September 17, 2025 and September 25, 2025, Alzamend Neuro, Inc. (the “ Company ”) issued an aggregate of 300,000 shares of common stock, par value $0.0001 per share (“ Common Stock ”) upon conversion of an aggregate of 696 shares of Series B Convertible Preferred Stock. The shares of Common Stock were issued in reliance upon exemption from the registration requirements under Section 4(a)(2) under the Securities Act. As of September 25, 2025, th…
Unregistered Sales of Equity Securities. Between July 23, 2025 and July 30, 2025, Alzamend Neuro, Inc. (the “ Company ”) issued an aggregate of 243,429 shares of common stock, par value $0.0001 per share (“ Common Stock ”) upon conversion of approximately 564.76 shares of Series B Convertible Preferred Stock. The shares of Common Stock were issued in reliance upon exemption from the registration requirements under Section 4(a)(2) under the Securities Act. As of July 30, 2025, the Company had…
and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing. The Securities and Exchange Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects of a registra…
Regulation FD Disclosure. On May 8, 2025, the Company issued a press release announcing the Reverse Stock Split, a copy of which press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. In accordance with General Instruction B.2 of Form 8-K, the information under this item, Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in an…
UNREGISTERED SALES OF EQUITY SECURITIES. The disclosure required by this Item and included in
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. On February 28, 2025 (the “ Execution Date ”), Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase & Exchange Agreement (the “ Agreement ”) with a sophisticated investor (the “ Purchaser ”), pursuant to which the Company agreed to (i) exchange the Purchaser’s 97.7511 shares of the Company’s Series A Convertible Preferred Stock (the “ Subject Shares ”) for an equal number of the Company’s Series C Convert…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.